Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma

SIMPLE SUMMARY: The introduction of immunotherapy into the treatment options for Hodgkin’s lymphoma has improved survival in patients with recurrence of their cancer. These agents help the body’s immune system respond and clear cancer cells. Currently, these agents are only approved in patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakhoda, Shazia, Rizwan, Farsha, Vistarop, Aldana, Nejati, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220999/
https://www.ncbi.nlm.nih.gov/pubmed/35740598
http://dx.doi.org/10.3390/cancers14122936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220999/
https://www.ncbi.nlm.nih.gov/pubmed/35740598
http://dx.doi.org/10.3390/cancers14122936

Ejemplares similares